Small font size A Larger text size A Largest text size A

Crispr Therapeutics Plans $350 Million Convertible Senior Notes Offering

BY MT Newswires | CORPORATE | 03/10/26 07:45 AM EDT

07:45 AM EDT, 03/10/2026 (MT Newswires) -- Crispr Therapeutics (CRSP) said Tuesday that it plans to offer $350 million of its convertible senior unsecured notes due March 1, 2031 in a private offering.

The company said it expects to grant the initial purchasers of the notes a 13-day option to buy up to an additional $52.5 million of the notes.

The company said it plans to use the net proceeds for general corporate purposes.

The interest rate, initial conversion rate and other terms of the offering will be decided upon pricing of the notes, the company said.

Crispr shares were down more than 7% in recent Tuesday premarket activity.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

More Fixed Income News

US prosecutors make surprise visit to Federal Reserve office BY Reuters |ECONOMIC 10:03 PM EDT
T1 Energy Announces Pricing of Upsized Public Offering of Convertible Senior Notes Due 2031 BY GlobeNewswire |CORPORATE 09:35 PM EDT
Treasury chief says US growth may exceed 3% or 3.5% this year despite Iran war BY Reuters |ECONOMIC 07:10 PM EDT
Treasury chief says US growth may exceed 3% or 3.5% this year despite Iran war BY Reuters |ECONOMIC 07:08 PM EDT

All Fixed Income News

In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.

Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.

fir_news_article